Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30133425 | 1.00 | ALDH1A1 (0.42) | ALDH1A1HSD17B10HIF1ACYP1B1CYP11B1 | |
| SCHEMBL29751038 | 1.00 | ALDH1A1 (0.42) | ALDH1A1HSD17B10HIF1ACYP1B1CYP11B1 | |
| SCHEMBL28216191 | 0.87 | PLAU (0.44) | ALDH1A1HSD17B10HIF1ACYP1B1CYP11B1 | |
| SCHEMBL30064841 | 0.77 | KDM4E (0.44) | ALDH1A1HSD17B10HIF1ACYP1B1HPGD | |
| SCHEMBL374938 | 0.77 | ALDH1A1 (0.39) | ALDH1A1HSD17B10HIF1ACYP1B1CYP11B1 | |
| SCHEMBL305348 | 0.77 | CYP1A2 (0.40) | ALDH1A1HSD17B10HIF1ACYP1B1HPGD | |
| SCHEMBL2519509 | 0.77 | CYP2A6 (0.47) | ALDH1A1HSD17B10HIF1ACYP1B1CYP11B1 | |
| SCHEMBL303815 | 0.77 | KDM4E (0.44) | ALDH1A1HSD17B10HIF1ACYP1B1HPGD | |
| SCHEMBL31165772 | 0.77 | CYP1A2 (0.45) | ALDH1A1HSD17B10HIF1ACYP1B1HPGD | |
| SCHEMBL4741365 | 0.77 | CYP1A2 (0.45) | ALDH1A1HSD17B10HIF1ACYP1B1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105384767-A | S,S-dioxo-dibenzothiophene onium salt based polymer precursor monomer and polymer, and preparation method therefor and application thereof | UNIV SOUTH CHINA TECH | 2016-03-09 | — | — | CN | claimed |
| US-12570671-B2 | Substituted oxoisoindoline compounds for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4126843-B1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20240300951-A1 | Pyrazolopyridinone Compounds | BEIGENE LTD. (KY) | 2024-09-12 | — | — | US | disclosed |
| US-20240270751-A1 | Pyrazolopyridinone Compounds | BEIGENE LTD. (KY) | 2024-08-15 | — | — | US | disclosed |
| CN-117836296-A | Pyrazolopyridone compounds | 百济神州有限公司 | 2024-04-05 | — | — | CN | disclosed |
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| WO-2023185986-A1 | BCL-XL INHIBITORS | BEIGENE , LTD. (KY) | 2023-10-05 | — | — | WO | disclosed |
| EP-4126843-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | Bristol-Myers Squibb Company (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115605466-A | Substituted oxoisoindoline compounds for the treatment of cancer | 百时美施贵宝公司（US） | 2023-01-13 | — | — | CN | disclosed |
| US-6875761-B2 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. (JP) | 2005-04-05 | — | — | US | disclosed |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. | 2004-10-14 | — | — | US | disclosed |
| US-6790844-B2 | MUSCLE RELAXANTS; ANTISEROTONINE AGENT | EISAI CO., LTD (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20040092740-A1 | Substituted pyridines and pyridazines with angiogenesis inhibiting activity | BAYER PHARMACEUTICALS CORPORATION | 2004-05-13 | — | — | US | disclosed |
| US-6689883-B1 | Substituted pyridines and pyridazines with angiogenesis inhibiting activity | BAYER PHARMACEUTICALS CORPORATION | 2004-02-10 | — | — | US | disclosed |
| EP-1228063-A2 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | Bayer Corporation (US) | 2002-08-07 | — | — | EP | disclosed |
| US-20020013460-A1 | Condensed pyridine compound | EISAI CO., LTD | 2002-01-31 | — | — | US | disclosed |
| US-6340759-B1 | ANTISPASMODIC AGENTS | EISAI CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| WO-2001023375-A2 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER CORPORATION (US) | 2001-04-05 | — | — | WO | disclosed |
| EP-1020445-A1 | FUSED PYRIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092740-A1 | Substituted pyridines and pyridazines with angiogenesis inhibiting activity | VEGFA, PGF, FLT1 | ALDH1A1 725/4885HSD17B10 2706/4885HIF1A 140/4885 |
| US-20020013460-A1 | Condensed pyridine compound | MUSK, HTR1A, PAX3 | ALDH1A1 2989/4885HSD17B10 3854/4885HIF1A 2778/4885 |
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | DDX21, HRAS, RPL17 | ALDH1A1 1946/4885HSD17B10 1771/4885HIF1A 1038/4885 |
| US-20240300951-A1 | Pyrazolopyridinone Compounds | NFATC1, CD4, PBK | ALDH1A1 1296/4885HSD17B10 3662/4885HIF1A 3188/4885 |
| US-12570671-B2 | Substituted oxoisoindoline compounds for the treatment of cancer | NR3C1, NR2C2, RIOX2 | ALDH1A1 3404/4885HSD17B10 2828/4885HIF1A 1577/4885 |
| US-20240270751-A1 | Pyrazolopyridinone Compounds | NFATC1, CD4, PBK | ALDH1A1 1296/4885HSD17B10 3662/4885HIF1A 3188/4885 |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | MUSK, HTR1A, RYR1 | ALDH1A1 1071/4885HSD17B10 3472/4885HIF1A 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.